pumecitinib vs Ruxolitinib (Opzelura)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: JAK1/2 · full Atopic Dermatitis pipeline
pumecitinib
Developed by Prime Gene Therapeutics and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Ruxolitinib (Opzelura)
Marketed by Incyte and partners
NCT03745638 · Phase 3 · completed
This was a randomized, quadruple-blinded, vehicle-controlled Phase 3 trial with 631 participants, comparing two doses of ruxolitinib cream against placebo. The primary endpoint was a clinician-assessed measure of disease severity (IGA treatment success at Week 8), and the comparison was met decisively: both ruxolitinib groups achieved significantly higher response rates than vehicle (50.0% and 53.8% vs 15.1%, each p<0.0001). The sample size was adequate, treatment assignment was concealed, and the hard clinical endpoint clearly favored active treatment.
Next expected readout: August 2027 · NCT07661979 (registry estimate)
Reported efficacy
Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 (Baseline to Week 8): Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 (Baseline to Week 8): VC Period: Ruxolitinib 0.75% Cream BID 50% (95% CI 43.7 to 56.3) | VC Period: Ruxolitinib 1.5% Cream BID 53.8% (95% CI 47.4 to 60) vs VC Period: Vehicle Cream BID 15.1% (95% CI 9.3 to 22.5) (met)
Result source: NCT03745638
Results for Atopic Dermatitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | pumecitinib | Ruxolitinib (Opzelura) |
|---|---|---|
| EASI-75 | —Trial running · NCT06587685 | 70% vs 18.5%+51.5 vs placeboNCT0623881721 other results
|
| IGA 0/1 with 2-point improvement | —Trial running · NCT06587685 | 15.7% vs 9.6%+6.1 vs placeboNCT0301189211 other results
|
| EASI-90 | —Trial running · NCT06587685 | 38.1% vs 9.5%+28.6 vs placeboNCT0374563811 other results
|
| EASI, % change | —Trial running · NCT06587685 | -71.0% vs -37.9%−33.1 vs placeboNCT0374563831 other results
|
EASI-75
- pumecitinib
- —Trial running · NCT06587685
- Ruxolitinib (Opzelura)
- 70% vs 18.5%+51.5 vs placeboNCT06238817
21 other results
- 56% vs 24.6% NCT03745638
- 62.1% vs 24.6% NCT03745638
- 51.5% vs 14.4% NCT03745651
- 61.8% vs 14.4% NCT03745651
- 51.5% vs 15.4% NCT04921969
- 67.2% vs 15.4% NCT04921969
- 51.6% vs 14.3% NCT03745638
- 58.5% vs 14.3% NCT03745638
- 42% vs 10.2% NCT03745651
- 50.4% vs 10.2% NCT03745651
- 53% vs 12.3% NCT04921969
- 62.6% vs 12.3% NCT04921969
- 30.2% vs 5.6% NCT03745638
- 36% vs 5.6% NCT03745638
- 25.5% vs 4.2% NCT03745651
- 31.6% vs 4.2% NCT03745651
- 35.8% vs 6.2% NCT04921969
- 43.5% vs 6.2% NCT04921969
- 33.3% vs 35.3% NCT05127421
- 29.2% vs 33.3% NCT05127421
- 10.4% vs 5.6% NCT05127421
IGA 0/1 with 2-point improvement
- pumecitinib
- —Trial running · NCT06587685
- Ruxolitinib (Opzelura)
- 15.7% vs 9.6%+6.1 vs placeboNCT03011892
11 other results
- 31.4% vs 9.6% NCT03011892
- 30.8% vs 9.6% NCT03011892
- 48% vs 9.6% NCT03011892
- 9.8% vs 7.7% NCT03011892
- 13.7% vs 7.7% NCT03011892
- 21.2% vs 7.7% NCT03011892
- 38% vs 7.7% NCT03011892
- 5.9% vs 1.9% NCT03011892
- 4.1% vs 1.9% NCT03011892
- 13.5% vs 1.9% NCT03011892
- 8% vs 1.9% NCT03011892
EASI-90
- pumecitinib
- —Trial running · NCT06587685
- Ruxolitinib (Opzelura)
- 38.1% vs 9.5%+28.6 vs placeboNCT03745638
11 other results
- 44.3% vs 9.5% NCT03745638
- 35.1% vs 4.2% NCT03745651
- 43.4% vs 4.2% NCT03745651
- 30.6% vs 4% NCT03745638
- 36.4% vs 4% NCT03745638
- 25.5% vs 2.5% NCT03745651
- 32.5% vs 2.5% NCT03745651
- 12.7% vs 2.4% NCT03745638
- 19.8% vs 2.4% NCT03745638
- 10.8% vs 0.8% NCT03745651
- 15.8% vs 0.8% NCT03745651
EASI, % change
- pumecitinib
- —Trial running · NCT06587685
- Ruxolitinib (Opzelura)
- -71.0% vs -37.9%−33.1 vs placeboNCT03745638
31 other results
- -77.4% vs -37.9% NCT03745638
- -73.4% vs -28.8% NCT03745651
- -74.8% vs -28.8% NCT03745651
- -68.0% vs -23.0% NCT03745638
- -71.1% vs -23.0% NCT03745638
- -65% vs -20.4% NCT03745651
- -66.3% vs -20.4% NCT03745651
- -51.8% vs -16.3% NCT03745638
- -56.6% vs -16.3% NCT03745638
- -45.9% vs -13.9% NCT03745651
- -49.1% vs -13.9% NCT03745651
- -71.6% vs -11.9% NCT03011892
- -50.2% vs -21.9% NCT03011892
- -58.4% vs -21.9% NCT03011892
- -67.0% vs -21.9% NCT03011892
- -79.0% vs -21.9% NCT03011892
- -44.9% vs -11.9% NCT03011892
- -52.8% vs -11.9% NCT03011892
- -66.7% vs -11.9% NCT03011892
- -45.4% vs -15.5% NCT03011892
- -52.2% vs -15.5% NCT03011892
- -67% vs -15.5% NCT03011892
- -71.6% vs -15.5% NCT03011892
- -30.0% vs -4.8% NCT03011892
- -45.9% vs -4.8% NCT03011892
- -49.9% vs -4.8% NCT03011892
- -52.7% vs -4.8% NCT03011892
- -44.9% vs -59.5% NCT03011892
- -52.8% vs -59.5% NCT03011892
- -66.7% vs -59.5% NCT03011892
- -71.6% vs -59.5% NCT03011892
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
pumecitinib: no structured comparison results are available for Atopic Dermatitis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. pumecitinib: 0 of 4 rows · Ruxolitinib (Opzelura): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ruxolitinib (Opzelura) |
|---|---|
| Dropout rate | —0.75% Creama NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 32 more results—1.5% Cream NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —0.75% Cream BID NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —1.5% Cream BID NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 11.9%0.75% Cream BID NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 11.1%1.5% Cream BID NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —0.75% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —1.5% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —0.75% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —1.5% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —0.75% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —1.5% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 15.7%0.75% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 8.9%1.5% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 10.7%1.5% Cream BID NCT05456529 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —0.75% Cream BID NCT04921969 · Phase 3 —1.5% Cream BID NCT04921969 · Phase 3 —0.75% Cream BID NCT04921969 · Phase 3 —1.5% Cream BID NCT04921969 · Phase 3 10.4%0.75% Cream BID NCT04921969 · Phase 3 12.2%1.5% Cream BID NCT04921969 · Phase 3 3.1%1.5% NCT06238817 · Phase 3 · registry result, not featured evidence 11.1%1.5% BID NCT05127421 · Phase 2 · registry result, not featured evidence —1.5% BID NCT05127421 · Phase 2 · registry result, not featured evidence —1.5% BID NCT05127421 · Phase 2 · registry result, not featured evidence 10.2%1.5% Cream BID NCT04839380 · Phase 2 · registry result, not featured evidence 13.7%0.5% QD NCT03011892 · Phase 2 · registry result, not featured evidence 10%1.5% BID NCT03011892 · Phase 2 · registry result, not featured evidence 13.5%1.5% QD NCT03011892 · Phase 2 · registry result, not featured evidence —0.15% QD NCT03011892 · Phase 2 · registry result, not featured evidence —0.5% QD NCT03011892 · Phase 2 · registry result, not featured evidence —1.5% BID NCT03011892 · Phase 2 · registry result, not featured evidence —1.5% QD NCT03011892 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —0.75% Creama NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 32 more results—1.5% Cream NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —0.75% Cream BID NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —1.5% Cream BID NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0.8%0.75% Cream BID NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0.4%1.5% Cream BID NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —0.75% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —1.5% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —0.75% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —1.5% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —0.75% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —1.5% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0.4%0.75% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0%1.5% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —1.5% Cream BID NCT05456529 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —0.75% Cream BID NCT04921969 · Phase 3 —1.5% Cream BID NCT04921969 · Phase 3 —0.75% Cream BID NCT04921969 · Phase 3 —1.5% Cream BID NCT04921969 · Phase 3 0.7%0.75% Cream BID NCT04921969 · Phase 3 0.8%1.5% Cream BID NCT04921969 · Phase 3 0%1.5% NCT06238817 · Phase 3 · registry result, not featured evidence —1.5% BID NCT05127421 · Phase 2 · registry result, not featured evidence —1.5% BID NCT05127421 · Phase 2 · registry result, not featured evidence —1.5% BID NCT05127421 · Phase 2 · registry result, not featured evidence —1.5% Cream BID NCT04839380 · Phase 2 · registry result, not featured evidence 0%0.5% QD NCT03011892 · Phase 2 · registry result, not featured evidence 0%1.5% BID NCT03011892 · Phase 2 · registry result, not featured evidence 0%1.5% QD NCT03011892 · Phase 2 · registry result, not featured evidence —0.15% QD NCT03011892 · Phase 2 · registry result, not featured evidence —0.5% QD NCT03011892 · Phase 2 · registry result, not featured evidence —1.5% BID NCT03011892 · Phase 2 · registry result, not featured evidence —1.5% QD NCT03011892 · Phase 2 · registry result, not featured evidence |
| Serious AEs | —0.75% Creama NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 32 more results—1.5% Cream NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 3%0.75% Cream BID NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 2%1.5% Cream BID NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —0.75% Cream BID NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —1.5% Cream BID NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —0.75% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —1.5% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —0.75% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —1.5% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 2.7%0.75% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 1.3%1.5% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —0.75% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —1.5% cream BID NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 1.9%1.5% Cream BID NCT05456529 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 —0.75% Cream BID NCT04921969 · Phase 3 —1.5% Cream BID NCT04921969 · Phase 3 0%0.75% Cream BID NCT04921969 · Phase 3 1.9%1.5% Cream BID NCT04921969 · Phase 3 —0.75% Cream BID NCT04921969 · Phase 3 —1.5% Cream BID NCT04921969 · Phase 3 2%1.5% NCT06238817 · Phase 3 · registry result, not featured evidence —1.5% BID NCT05127421 · Phase 2 · registry result, not featured evidence —1.5% BID NCT05127421 · Phase 2 · registry result, not featured evidence 0%1.5% BID NCT05127421 · Phase 2 · registry result, not featured evidence 0%1.5% Cream BID NCT04839380 · Phase 2 · registry result, not featured evidence —0.5% QD NCT03011892 · Phase 2 · registry result, not featured evidence —1.5% BID NCT03011892 · Phase 2 · registry result, not featured evidence —1.5% QD NCT03011892 · Phase 2 · registry result, not featured evidence 0%0.15% QD NCT03011892 · Phase 2 · registry result, not featured evidence 0%0.5% QD NCT03011892 · Phase 2 · registry result, not featured evidence 0%1.5% BID NCT03011892 · Phase 2 · registry result, not featured evidence 0%1.5% QD NCT03011892 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 0.75% Cream BIDa upper respiratory tract infection 9% (placebo 3.2%) nasopharyngitis 6% (placebo 1.6%) headache 3.7% (placebo 4%) NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 13 more results1.5% Cream BID upper respiratory tract infection 12% (placebo 3.2%) nasopharyngitis 10.3% (placebo 1.6%) headache 5.3% (placebo 4%) NCT03745638 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0.75% cream BID nasopharyngitis 9.3% (placebo 0%) upper respiratory tract infection 7.6% (placebo 0.8%) application site pain 0.7% (placebo 6.5%) NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 1.5% cream BID nasopharyngitis 9.1% (placebo 0%) upper respiratory tract infection 7.7% (placebo 0.8%) application site pain 0.7% (placebo 6.5%) NCT03745651 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 1.5% Cream BID upper respiratory tract infection 10.7% nasopharyngitis 8.7% NCT05456529 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0.75% Cream BID upper respiratory tract infection 13.8% (placebo 3.1%) covid-19 8.2% (placebo 1.5%) pyrexia 6.3% (placebo 0%) NCT04921969 · Phase 3 1.5% Cream BID upper respiratory tract infection 14.9% (placebo 3.1%) nasopharyngitis 13% (placebo 1.5%) covid-19 7.1% (placebo 1.5%) NCT04921969 · Phase 3 1.5% upper respiratory tract infection 10.3% (placebo 4.9%) nasopharyngitis 5.9% (placebo 4.9%) application site pain 1% (placebo 6.2%) NCT06238817 · Phase 3 · registry result, not featured evidence 1.5% BID application site reaction 1.4% (placebo 8.7%) NCT05127421 · Phase 2 · registry result, not featured evidence 1.5% Cream BID covid-19 6.1% back pain 4.1% headache 4.1% NCT04839380 · Phase 2 · registry result, not featured evidence 0.15% QD nasopharyngitis 5.9% (placebo 7.7%) upper respiratory tract infection 3.9% (placebo 5.8%) dermatitis atopic 2% (placebo 7.7%) NCT03011892 · Phase 2 · registry result, not featured evidence 0.5% QD nasopharyngitis 2% (placebo 7.7%) upper respiratory tract infection 2% (placebo 5.8%) dermatitis atopic 0% (placebo 7.7%) NCT03011892 · Phase 2 · registry result, not featured evidence 1.5% BID nasopharyngitis 5% (placebo 7.7%) upper respiratory tract infection 2.7% (placebo 5.8%) dermatitis atopic 1.5% (placebo 7.7%) NCT03011892 · Phase 2 · registry result, not featured evidence 1.5% QD nasopharyngitis 7.8% (placebo 7.7%) dermatitis atopic 3.9% (placebo 7.7%) upper respiratory tract infection 2% (placebo 5.8%) NCT03011892 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 18 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ruxolitinib (Opzelura)
show 17 more results
show 21 more results
show 5 more results
show 5 more results
show 5 more results
show 12 more results
show 71 more results
show 23 more results
show 11 more results
show 31 more results
show 11 more results
show 23 more results
+ 57 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: pumecitinib's landscape · Ruxolitinib (Opzelura)'s landscape